Editorial Board
Bridget Bax
St George's University of London · United Kingdom
Editorial leadership for International Journal of Personalized Medicine
Research interests
- Rare Diseases
- Cell Based Therapies
Biography
- Diagnosis delays, lack of comprehension of disease pathophysiology, poor co-ordination of care and no approved therapies are the challenges that face a majority of the rare disease community.
- Over 7,000 rare diseases have been identified, but to date there are only around 400 licenced treatments on the market, creating a huge unmet need.
- Currently her team are focusing on the fatal, ultra-rare disease, mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
Dr Bax’s research focuses on two objectives:
i) to improve the understanding of the underlying pathogenic molecular mechanisms of rare inherited diseases and
ii) to develop cell-based therapies for diseases with unmet needs.
Selected publications
- Erythrocyte Encapsulated Thymidine Phosphorylase for the Treatment of Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy: Study Protocol for a Multi-Centre, Multiple Dose, Open Label Trial 2019 cited 45×
- Safety and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase in Mitochondrial Neurogastrointestinal Encephalomyopathy 2019 cited 44×
- Biomarkers in Rare Diseases 2021 cited 23×
- Erythrocytes as Carriers of Therapeutic Enzymes 2020 cited 22×
- Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy 2020 cited 9×
- Circulating miRNAs as Biomarkers for Mitochondrial Neuro-Gastrointestinal Encephalomyopathy 2021 cited 7×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering IJPM for your work?
This journal is guided by Bridget Bax (St George's University of London) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.